NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's Green Ibuprofen Process Publication in RSC Sustainability
TL;DR
Quantumzyme's enzymatic ibuprofen process offers pharmaceutical companies a competitive edge through reduced production costs and superior environmental credentials.
Quantumzyme engineered aldehyde dehydrogenase enzymes using computational modeling to create a streamlined, multi-step ibuprofen synthesis with improved yield and efficiency.
This green ibuprofen synthesis reduces hazardous chemical use and environmental impact, advancing sustainable pharmaceutical manufacturing for a healthier planet.
Quantumzyme used computer-designed enzymes to create ibuprofen through an eco-friendly biological process instead of traditional chemical manufacturing methods.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme announced the publication of its pioneering research on sustainable ibuprofen synthesis in RSC Sustainability, validating their breakthrough enzymatic process for eco-friendly ibuprofen production.
This innovation provides a green, efficient, and scalable alternative to traditional chemical synthesis, significantly reducing reliance on harsh reagents, minimizing reaction steps, and improving yield while aligning with global green chemistry goals.
The process leverages computational enzyme engineering and digital biology to design high-performance biocatalysts, specifically engineering aldehyde dehydrogenase for eco-friendly ibuprofen synthesis through in silico enzyme design.
The research was published in RSC Sustainability, a flagship journal of the Royal Society of Chemistry, with the article titled 'In silico enzyme engineering of aldehyde dehydrogenase for eco-friendly ibuprofen synthesis' (DOI: 10.1039/D5SU00073D).
Naveen Kulkarni serves as CEO of Quantumzyme Corp., and he stated that this publication validates their vision to transform pharmaceutical manufacturing through sustainable innovation.
The process reduces environmental footprint, minimizes waste, improves efficiency, demonstrates potential for large-scale Active Pharmaceutical Ingredient (API) manufacturing, and aligns with sustainability goals while being cost-effective and scalable.
The announcement was made on November 5, 2025, as indicated in the press release from Quantumzyme Corp.
Quantumzyme Corp. is a biotransformation company specializing in computational enzyme engineering, green chemistry, and sustainable biocatalysis solutions, using quantum mechanics, molecular modeling, and AI-driven simulations to design high-performance biocatalysts.
The full article can be accessed at RSC Sustainability using DOI: 10.1039/D5SU00073D, and more information is available on Quantumzyme's website at www.quantumzymecorp.com.
This milestone reinforces Quantumzyme's commitment to sustainable pharmaceutical technologies and paves the way for cleaner, smarter, and future-ready solutions that could make eco-friendly biocatalysis the industry standard.
Curated from NewMediaWire
